1. Home
  2. GNRC vs NBIX Comparison

GNRC vs NBIX Comparison

Compare GNRC & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generac Holdlings Inc.

GNRC

Generac Holdlings Inc.

HOLD

Current Price

$207.28

Market Cap

11.8B

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$128.81

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNRC
NBIX
Founded
1959
1992
Country
United States
United States
Employees
9400
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8B
13.2B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
GNRC
NBIX
Price
$207.28
$128.81
Analyst Decision
Buy
Strong Buy
Analyst Count
18
22
Target Price
$209.06
$180.36
AVG Volume (30 Days)
918.1K
906.6K
Earning Date
04-29-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.95
EPS
N/A
4.67
Revenue
N/A
$161,626,000.00
Revenue This Year
$17.46
$22.85
Revenue Next Year
$12.44
$10.36
P/E Ratio
$84.89
$28.21
Revenue Growth
N/A
977.51
52 Week Low
$104.90
$92.32
52 Week High
$241.09
$160.18

Technical Indicators

Market Signals
Indicator
GNRC
NBIX
Relative Strength Index (RSI) 54.51 45.23
Support Level $195.41 $124.09
Resistance Level $238.55 $136.74
Average True Range (ATR) 9.36 4.22
MACD 0.93 0.16
Stochastic Oscillator 83.59 40.54

Price Performance

Historical Comparison
GNRC
NBIX

About GNRC Generac Holdlings Inc.

Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: